Center for Drug Evaluation and Research growing crisis around HIV testing and treatment and an inter-agency dispute between officials from the former Bureau of Drugs and officials from the former Bureau of Biologics over whether to approve Genentech's Activase (tissue plasminogen activator) led to the split. In its original form, CDER was composed of six offices: Management, Compliance, Drug Standards, Drug Evaluation I, Drug Evaluation II, Epidemiology and Biostatistics, and Research Resources. The Division of Antiviral Products was added in 1989 under Drug Evaluation II due to the large amount of drugs proposed for treating AIDS. The Office of Generic Drugs was also formed. In 2002,
Heterogeneous condition also define a "medical condition" as any illness, injury, or disease except for psychiatric illnesses. As it is more value-neutral than terms like "disease", the term "medical condition" is sometimes preferred by people with health issues that they do not consider deleterious. It is also preferred when etiology is not unique, because the word disease is normally associated to the cause of the clinical problems. On the other hand, by emphasizing the medical nature of the condition, this term is sometimes rejected, such as by proponents of the autism rights movement. The term is also used in specialized areas of